Atika Capital Management LLC
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1599731
NEW YORK, NY
Position in PTGX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,612,217
+$1,066,878 QoQ
Shares Held
62,100
0.0% QoQ
Ownership
0.096%
of shares outstanding
% of Portfolio
0.76%
of 13F equity value
Holder Rank
#81
of 341 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Atika Capital Management LLC holds $138,478,275 across 17 Biotechnology names. PTGX ranks #9 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
88,000 | $16,480,639 | |
| 2 | ASND |
Ascendis Pharma A/S
|
61,000 | $16,269,919 | |
| 3 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
165,000 | $16,084,198 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
63,000 | $15,420,508 | |
| 5 | KYMR |
Kymera Therapeutics, Inc.
|
104,000 | $11,925,678 | |
| 6 | COGT |
Cogent Biosciences, Inc.
|
272,000 | $10,526,399 | |
| 7 | ORKA |
Oruka Therapeutics, Inc.
|
100,000 | $9,516,998 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
217,000 | $7,679,628 |
All Filings in PTGX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,612,217 | 62,100 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $6,545,339 | 62,100 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $7,511,239 | 86,000 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $5,513,689 | 83,000 | Shares | Defined | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||